Longitudinal effects of the SSRI paroxetine on salivary cortisol in Major Depressive Disorder

Psychoneuroendocrinology

Volumn 52, Issue 1, 2015, Pages 261-271

  Ruhé, Henricus G ^a,b   Khoenkhoen, Sharina J ^a   Ottenhof, Koen W ^a   Koeter, Maarten W ^a   Mocking, Roel J T ^a   Schene, Aart H ^a,c,d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY   (Netherlands)

Author keywords

Cortisol; Depressive disorder; HPA axis; Remission; SSRI; Treatment response

Indexed keywords

HYDROCORTISONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AREA UNDER THE CURVE; AROUSAL; ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; FEMALE; HUMAN; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SALIVA LEVEL; CHEMISTRY; DRUG EFFECTS; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM; MIDDLE AGED; SALIVA; TREATMENT OUTCOME;

ADULT; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PAROXETINE; PITUITARY-ADRENAL SYSTEM; SALIVA; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84922680332     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2014.10.024     Document Type: Article

References (53)

1. Adam, E.K., Doane, L.D., Zinbarg, R.E., Mineka, S., Craske, M.G.,Griffith, J.W., 2010. Prospective prediction of major depressive disorder from cortisol awakening responses in adolescence.Psychoneuroendocrinology 35, 921-931.
2. Adli, M., Baethge, C., Heinz, A., Langlitz, N., Bauer, M., 2005. Isdose escalation of antidepressants a rational strategy after amediumdose treatment has failed? A systematic review. Eur.Arch. Psychiatry Clin. Neurosci. 255, 387-400.
3. Aihara, M., Ida, I., Yuuki, N., Oshima, A., Kumano, H., Takahashi,K., et al., 2007. HPA axis dysfunction in unmedicated majordepressive disorder and its normalization by pharmacotherapycorrelates with alteration of neural activity in prefrontal cortexand limbic/paralimbic regions. Psychiatry Res. 155, 245-256.
4. Appelhof, B.C., Huyser, J., Verweij, M., Brouwer, J.P., Van Dyck,R., Fliers, E., et al., 2006. Glucocorticoids and relapse ofmajor depression (dexamethasone/corticotropinreleasing hormone test in relation to relapse of major depression). Biol.Psychiatry 59, 696-701.
5. Aubry, J.M., Jermann, F., GexFabry, M., Bockhorn, L., Van der Lin-den, M., Gervasoni, N., et al., 2010. The cortisol awakeningresponse in patients remitted from depression. J. Psychiatr. Res.44, 1199-1204.
6. Bartak, A., Spreeuwenberg, M.D., Andrea, H., Busschbach, J.J.V.,Croon, M.A., Verheul, R., et al., 2009. The use of propensityscore methods in psychotherapy research. Psychother. Psychosom. 78, 26-34.
7. Bhagwagar, Z., Hafizi, S., Cowen, P.J., 2003. Increase in concentration of waking salivary cortisol in recovered patients withdepression. Am. J. Psychiatry 160, 1890-1891.
8. Bhagwagar, Z., Hafizi, S., Cowen, P.J., 2005. Increased salivarycortisol after waking in depression. Psychopharmacology (Berl.)182, 54-57.
9. Bockting, C.L., Lok, A., Visser, I., Assies, J., Koeter, M.W., Schene,A.H., 2012. Lower cortisol levels predict recurrence in remittedpatients with recurrent depression: a 5.5 year prospective study.Psychiatry Res. 200, 281-287.
10. Bschor, T., Ising, M., Erbe, S., Winkelmann, P., Ritter, D., Uhr, M.,et al., 2012. Impact of citalopram on the HPA system. A study ofthe combined DEX/CRH test in 30 unipolar depressed patients.J. Psychiatr. Res. 46, 111-117.
11. Buhl, E.S., Jensen, T.K., Jessen, N., Elfving, B., Buhl, C.S.,Kristiansen, S.B., et al., 2010. Treatment with an SSRIantidepressant restores hippocampo hypothalamic corticosteroid feedback and reverses insulin resistance in low-birth-weightrats. Am. J. Physiol. Endocrinol. Metab. 298, E920-E929.
12. Chida, Y., Steptoe, A., 2009. Cortisol awakening response and psychosocial factors: a systematic review and meta analysis. Biol.Psychol. 80, 265-278.
13. Clow, A., Thorn, L., Evans, P., Hucklebridge, F., 2004. The awakening cortisol response: methodological issues and significance.Stress 7, 29-37.
14. De Bellis, M.D., Gold, P.W., Geracioti Jr., T.D., Listwak, S.J., Kling,M.A., 1993. Association of fluoxetine treatment with reductionsin CSF concentrations of corticotropin-releasing hormone andarginine vasopressin in patients with major depression. Am. J.Psychiatry 150, 656-657.
15. Deuschle, M., Hamann, B., Meichel, C., Krumm, B., Lederbogen, F., Kniest, A., et al., 2003. Antidepressive treatment withamitriptyline and paroxetine: effects on saliva cortisol concentrations. J. Clin. Psychopharmacol. 23, 201-205.
16. Evans, P., Fredhoi, C., Loveday, C., Hucklebridge, F., Aitchison, E.,Forte, D., Clow, A., 2011. The diurnal cortisol cycle and cognitive performance in the healthy old. Int. J. Psychophysiol. 79,371-377.
17. Fries, E., Dettenborn, L., Kirschbaum, C., 2009. The cortisolawakening response (CAR): facts and future directions. Int. J.Psychophysiol. 72, 67-73.
18. Gallagher, P., Leitch, M.M., Massey, A.E., Lister Williams, R.H.,Young, A.H., 2006. Assessing cortisol and dehydroepiandrosterone (DHEA) in saliva: effects of collection method. J.Psychopharmacol. 20, 643-649.
19. Hajat, A., Diez-Roux, A., Franklin, T.G., Seeman, T., Shrager,S., Ranjit, N., et al., 2010. Socioeconomic and race/ethnicdifferences in daily salivary cortisol profiles: the multiethnic study of atherosclerosis. Psychoneuroendocrinology 35,932-943.
20. Hardeveld, F., Spijker, J., Vreeburg, S.A., Graaf, R., Hendriks,S.M., Licht, C.M., Nolen, W.A., Penninx, B.W., Beekman, A.T.,2014. Increased cortisol awakening response was associated withtime to recurrence of major depressive disorder. Psychoneuroendocrinology 50C, 62-71, http://dx.doi.org/10.1016/j.psyneuen.2014.07.027.
21. Harmer, C.J., Bhagwagar, Z., Shelley, N., Cowen, P.J., 2003. Contrasting effects of citalopram and reboxetine on waking salivarycortisol. Psychopharmacology (Berl.) 167, 112-114.
22. Heuser, I., Yassouridis, A., Holsboer, F., 1994. The combined dexamethasone/CRH test: a refined laboratory test for psychiatricdisorders. J. Psychiatr. Res. 28, 341-356.
23. Holsboer, F., 2000. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23, 477-501.
24. Huber, T.J., Issa, K., Schik, G., Wolf, O.T., 2006. The cortisol awakening response is blunted in psychotherapy inpatients suffering from depression. Psychoneuroendocrinology 31,900-904.
25. Jaeger, T.F., 2008. Categorical data analysis: away from ANOVAs(transformation or not) and towards logit mixed models. J. Mem.Lang. 59, 434-446.
26. Kirschbaum, C., Hellhammer, D.H., 1994. Salivary cortisol inpsychoneuroendocrine research: recent developments andapplications. Psychoneuroendocrinology 19, 313-333.
27. Kudielka, B.M., Hellhammer, D.H., Wust, S., 2009. Why do werespond so differently? Reviewing determinants of human salivary cortisol responses to challenge. Psychoneuroendocrinology34, 2-18.
28. Kunugi, H., Hori, H., Adachi, N., Numakawa, T., 2010. Interfacebetween hypothalamic-pituitary-adrenal axis and brain-derivedneurotrophic factor in depression. Psychiatry Clin. Neurosci. 64,447-459.
29. Lamers, F., Vogelzangs, N., Merikangas, K.R., de, J.P., Beekman,A.T., Penninx, B.W., 2013. Evidence for a differential roleof HPA-axis function, inflammation and metabolic syndromein melancholic versus atypical depression. Mol. Psychiatry 18,692-699.
30. Law, R., Hucklebridge, F., Thorn, L., Evans, P., Clow, A., 2013.State variation in the cortisol awakening response. Stress 16,483-492.
31. Lenze, E.J., Mantella, R.C., Shi, P., Goate, A.M., Nowotny, P., Butters, M.A., et al., 2010. Elevated cortisol in older adults withgeneralized anxiety disorder is reduced by treatment: a placebo controlled evaluation of escitalopram. Am. J. Geriatr. Psychiatry19, 482-490.
32. Lok, A., Mocking, R.J., Ruhe, H.G., Visser, I., Koeter, M.W., Assies,J., et al., 2011. Longitudinal hypothalamicpituitary-adrenalaxis trait and state effects in recurrent depression. Psychoneuroendocrinology 37, 892-902.
33. Nikisch, G., Mathe, A.A., Czernik, A., Thiele, J., Bohner, J., Eap,C.B., et al., 2005. Long-term citalopram administration reducesresponsiveness of HPA axis in patients with major depression:relationship with Scitalopram concentrations in plasma andcerebrospinal fluid (CSF) and clinical response. Psychopharmacology (Berl.) 181, 751-760.
34. Pariante, C.M., 2009. Risk factors for development of depressionand psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressant and glucocorticoids.Ann. N. Y. Acad. Sci. 1179, 144-152.
35. Pruessner, M., Hellhammer, D.H., Pruessner, J.C., Lupien, S.J.,2003. Self reported depressive symptoms and stress levels inhealthy young men: associations with the cortisol response toawakening. Psychosom. Med. 65, 92-99.
36. Rosenbaum, P.R., Rubin, D.B., 1983. The central role of the propensity score in observational studies for causal effects. Biometrika70, 41-55.
37. Ruhe, H.G., Booij, J., Weert, H.C., Reitsma, J.B., Franssen, E.J.,Michel, M.C., et al., 2009. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomizedcontrolled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology 34, 999-1010.
38. Ruhe, H.G., Huyser, J., Swinkels, J.A., Schene, A.H., 2006. Doseescalation for insufficient response to standard dose selectiveserotonin reuptake inhibitors in major depressive disorder: systematic review. Br. J. Psychiatry 189, 309-316.
39. Ruhe, H.G., van, R.G., Spijker, J., Peeters, F.P., Schene, A.H., 2012.Staging methods for treatment resistant depression. A systematic review. J. Affect. Disord. 137, 35-45.
40. Schule, C., 2007. Neuroendocrinological mechanisms of actions ofantidepressant drugs. J. Neuroendocrinol. 19, 213-226.
41. Shelton, R.C., 2007. The molecular neurobiology of depression.Psychiatr. Clin. North Am. 30, 1-11.
42. Stalder, T., Hucklebridge, F., Evans, P., Clow, A., 2009. Use of asingle case study design to examine state variation in the cortisol awakening response: relationship with time of awakening.Psychoneuroendocrinology 34, 607-614.
43. Stetler, C., Miller, G.E., 2011. Depression and hypothalamicpituitary-adrenal activation: a quantitative summary of fourdecades of research. Psychosom. Med. 73, 114-126.
44. Stetler, C., Miller, G.E., 2005. Blunted cortisol response to awakening in mild to moderate depression: regulatory influences ofsleep patterns and social contacts. J. Abnorm. Psychol. 114,697-705.
45. Thorn, L., Evans, P., Cannon, A., Hucklebridge, F., Clow, A., 2011.Seasonal differences in the diurnal pattern of cortisol secretionin healthy participants and those with self assessed seasonalaffective disorder. Psychoneuroendocrinology 36, 816-823.
46. Veen, G., van Vliet, I.M., Derijk, R.H., Giltay, E.J., van, P.J., Zitman,F.G., 2011. Basal cortisol levels in relation to dimensions and DSM-IV categories of depression and anxiety. Psychiatry Res. 185,121-128.
47. Vermetten, E., Vythilingam, M., Schmahl, C.D.E.K.C., Southwick,S.M., Charney, D.S., et al., 2006. Alterations in stress reactivityafter longterm treatment with paroxetine in women with post traumatic stress disorder. Ann. N. Y. Acad. Sci. 1071, 184-202.
48. Vreeburg, S.A., Hartman, C.A., Hoogendijk, W.J., van, D.R., Zitman, F.G., Ormel, J., et al., 2010. Parental history of depressionor anxiety and the cortisol awakening response. Br. J. Psychiatry197, 180-185.
49. Vreeburg, S.A., Hoogendijk, W.J., van, P.J., Derijk, R.H., Verhagen, J.C., van, D.R., et al., 2009. Major depressive disorder andhypothalamicpituitary-adrenal axis activity: results from a largecohort study. Arch. Gen. Psychiatry 66, 617-626.
50. Vrshek-Schallhorn, S., Doane, L.D., Mineka, S., Zinbarg, R.E.,Craske, M.G., Adam, E.K., 2013. The cortisol awakeningresponse predicts major depression: predictive stability over a4-year followup and effect of depression history. Psychol. Med.43, 483-493.
51. Wardenaar, K.J., Vreeburg, S.A., van, V.T., Giltay, E.J., Veen, G.,Penninx, B.W., et al., 2011. Dimensions of depression and anxiety and the hypothalamo pituitary-adrenal axis. Biol. Psychiatry69, 366-373.
52. Westermann, J., Demir, A., Herbst, V., 2004. Determination of cortisol in saliva and serum by a luminescence enhanced enzymeimmunoassay. Clin. Lab. 50, 11-24.
53. Wust, S., Wolf, J., Hellhammer, D.H., Federenko, I., Schommer, N.,Kirschbaum, C., 2000. The cortisol awakening response - normalvalues and confounds. Noise Health 2, 79-88.